This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal

P3 Prostate Cancer Forum 2025

P3 background - Article

The P3 Prostate Cancer Forum took place on the 16th and 17th May 2025. It was dedicated to offering education and diverse expert perspectives on the latest advancements in the field, providing in-depth insights into the treatment and care of patients with advanced prostate cancer.

This promotional meeting has been initiated and funded by Bayer UK and is for UK Healthcare professionals only.

Exploring the mHSPC Patient Journey
Join experts for evidence-based treatment strategies on the application of triple therapy in mHSPC.
PP-NUB-GB-2382, June 2025
Resources to support prostate cancer patients
A focus on drug-to-drug interactions, managing risk and navigating around psychosexual health.
PP-NUB-GB-2385, June 2025
Finding consensus on utilising triplet therapy in mHSPC p...
Discussing triplet therapy in low-burden metastatic hormone-sensitive prostate cancer (mHSPC).
PP-NUB-GB-2383, June 2025

Meet our speakers for the event, starting with our meeting chairs: Professor Alison Birtle, Professor Amit Bahl and Mr William Cross. Supported by our Keynote Speaker Professor Fred Saad.

Amit Bahl P3
William Cross P3
Alison Birtle P3
Fred Saad P3

The landscape of prostate cancer is rapidly evolving. Professor Fred Saad welcomed the delegates at P3 Prostate Cancer Forum, and gave an update on the implications of new treatment advances and emerging therapies and research trends. 

Presented by Professor Fred Saad - Prostate Cancer: The Past, Present and Future.

NUBEQA (darolutamide) Prescribing Information

Xofigo▼ (radium-223 dichloride) Prescribing Information

PP-NUB-GB-2381, June 2025 

Exploring the mHSPC Patient Journey
Join experts for evidence-based treatment strategies on the application of triple therapy in mHSPC.
PP-NUB-GB-2382, June 2025
Resources to support prostate cancer patients
A focus on drug-to-drug interactions, managing risk and navigating around psychosexual health.
PP-NUB-GB-2385, June 2025
Finding consensus on utilising triplet therapy in mHSPC p...
Discussing triplet therapy in low-burden metastatic hormone-sensitive prostate cancer (mHSPC).
PP-NUB-GB-2383, June 2025